All News
SGLT2 Inhibitor Protective Effects in Lupus
Systemic lupus erythematosus (SLE) outcomes were assessed based on whether they received sodium-glucose co-transporter 2 inhibitors (SGLT2i), in the setting of comorbid type 2 diabetes (T2D).
Read Article
Filgotinib Efficacy and Safety - 3 Years Later
d
MedPage Today
Filgotinib, the rheumatoid arthritis (RA) oral drug that never made it to the U.S. market but is sold across Europe, Great Britain, and Japan, remained effective for 3 years for most registration trial participants who continued in a long-term extension study, researchers said.
Read Article
Swapping is Better than Cycling in Psoriatic Arthritis
A real-world cohort study suggests that psoriatic arthritis failing to respond to TNF inhibitors (TNFi) may do better if they subsequently swap to an IL-17 inhibitor, rather than cycling to another TNFi.
Read Article
Treatment Options for Dupuytren’s Contracture
The NEJM reports that in a randomized, controlled, head to head trial, collagenase injections were non-inferior to limited fasciectomy in the treatment of Dupuytren’s contracture.
Read Article
Blue Collar Arthritis (10.25.2024)
Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.
https://t.co/INcke6eLLC https://t.co/TGyxzmCrjv
Dr. John Cush RheumNow ( View Tweet)
Real-world study of 76 #PsA pts (Dz Duration Psoriasis 216 mos, PsA 120 mos. No correlatons seen between skin/PASI scores and PsA clinical variables, except the signif correlation betw PASI & enthesitis (ρ = 0.285; p = 0.013). https://t.co/K6FXjE5A4N https://t.co/NVlPiPVT0s
Dr. John Cush RheumNow ( View Tweet)
Airway Dz in RA (w/o ILD dx) studied in 188 pts. Airways obst. in 21% by PFTs (assoc w/ older, male, smoking). CXR abnl in 61%, (55% bronchial thickening, 12% bronchiectasis), esp in RF+.
Quant CT scan measures correlated w/ respiratory symptoms https://t.co/In1sxLZQRm https://t.co/anmUNGuby8
Dr. John Cush RheumNow ( View Tweet)
Biomarkers in ILD: Small cohort study of 55 pts suggest potential biomakers: Cancer antigen 15-3, MMP-7, Surfactant protein D, MIP-1β, & chitinase 3-like protein-1 (YKL-40). https://t.co/S5bokc0SNi https://t.co/kLKjnyuK8p
Links:
Dr. John Cush RheumNow ( View Tweet)
Trends in DMARD Use in Juvenile Arthritis 2001-2022
Arthritis & Rheumatology reports that treatment trends in juvenile idiopathic arthritis (JIA) in the last two decades finds rising use of newer biologic and targeted synthetic DMARDs coupled with a decline in conventional… https://t.co/fEOvjm21lY https://t.co/LfDleabEQS
Dr. John Cush RheumNow ( View Tweet)
SPRINGBOARD: Extended-release Intra-articular Corticosteroid Injection in Knee OA
A phase 2 trial of EP-104IAR (long-acting, fluticasone propionate) has shown 14 weeks of clinically meaningful pain relief in knee osteoarthritis (OA). This intra-articular formulation is… https://t.co/IjlEDMmzzH https://t.co/Ly40yQgZ8e
Dr. John Cush RheumNow ( View Tweet)
Calcium pyrophosphate deposition disease -- a full access, full read review in Lancet Rheumatology. Just published ahttps://buff.ly/3C319CH https://t.co/PxywxvzVCh
Dr. John Cush RheumNow ( View Tweet)
Nailfold videocapillaroscopy (NVC) study of 65 Behcets pts found vascular abnl in 40-47% ( enlarged/tortuous capillaries, microhaemorrhages. Having ≥2 NVC abnormalities increase risk of Vascular events (VTE, superficial thrombophlebitis), but not ANA https://t.co/2Om0IIFVnG https://t.co/W7mbdPh9ee
Dr. John Cush RheumNow ( View Tweet)
Pain Relief in RA: JAK Better than TNF Inhibitors?
Targeted drugs for rheumatoid arthritis (RA) are not created equal when it comes to pain relief, a retrospective study from Sweden indicated, although the differences appeared to be modest.
https://t.co/olXQMGm2h8 https://t.co/Em7ydT33Ui
Dr. John Cush RheumNow ( View Tweet)
Ganglion cysts are thin walled cavities contain a viscous, mucinous fluid, arising in proximity to joint capsules/tendon sheaths but do not communicate with the joint. Most common w/ repetitive strain or overuse, trauma, or inflam. arthritis. Steroid injx dont… https://t.co/nUlQvemYa5 https://t.co/gSNzBuPeW4
Dr. John Cush RheumNow ( View Tweet)
RBC mitochondrial DNA triggers type I interferon (IFN) production in macrophages leading to production of interleukin-1β and inflammasome activation - Making IFN & IL-1B monocytes another potential therapeutic target in #SLE https://t.co/DeZH1RT3GC https://t.co/jojAhNoNzA https://t.co/lPuOQxvmVb
Links:
Dr. John Cush RheumNow ( View Tweet)
Full read review on the detection & management of #ILD in Autoimmune Dz (AID).
- AID at risk for ILD should be screened with hi-res CT Scan
- ILD should be monitored closely w/ PFTs
- Multidisciplinary Rx includes immunosuppressives & antifibrotics https://t.co/X6Feor2wF5 https://t.co/Z2WBWL3q1W
Dr. John Cush RheumNow ( View Tweet)
Early bird pricing ends 10/31. Secure your seat for RheumNow Live today!
https://t.co/TBNLxfBbEF https://t.co/6OLHEXCvUw
Links:
Dr. John Cush RheumNow ( View Tweet)
Potential OA Treatment - Chemokine CCL17 Inhibition
Patients with osteoarthritis (OA) of the knee receiving an investigational chemokine inhibitor showed some improvements in pain and disability, said researchers with the drug's developer.
https://t.co/MYYBBIIuDA https://t.co/1AfbxCuGIq
Dr. John Cush RheumNow ( View Tweet)
Heritability of asymptomatic ANA positivity is 25%. Asymptomatic ANA positive individuals did not exhibit increased cumulative genetic risk for lupus compared to ANA negative individuals. Genetic study of 1,955 asymptomatic ANA+ v 3,634 asymptomatic ANAnegs.… https://t.co/P0MmFfG7NV https://t.co/KnlyNPKG4s
Dr. John Cush RheumNow ( View Tweet)
Long-term Tofacitinib in Juvenile Idiopathic Arthritis
The long-term safety and efficacy of tofacitinib in patients with juvenile idiopathic arthritis (JIA) has been established in an ongoing long term extension (LTE) study.
https://t.co/IKHM6z8iMB https://t.co/O6ig1lTQR4
Dr. John Cush RheumNow ( View Tweet)